CN117320759A - 放射性药物生长抑素受体配体及其前体 - Google Patents

放射性药物生长抑素受体配体及其前体 Download PDF

Info

Publication number
CN117320759A
CN117320759A CN202280035052.5A CN202280035052A CN117320759A CN 117320759 A CN117320759 A CN 117320759A CN 202280035052 A CN202280035052 A CN 202280035052A CN 117320759 A CN117320759 A CN 117320759A
Authority
CN
China
Prior art keywords
group
acid
unit
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280035052.5A
Other languages
English (en)
Chinese (zh)
Inventor
H-J·韦斯特
M·帕辛格
M·F·法瑙尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
Original Assignee
Technische Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen filed Critical Technische Universitaet Muenchen
Publication of CN117320759A publication Critical patent/CN117320759A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202280035052.5A 2021-05-14 2022-05-12 放射性药物生长抑素受体配体及其前体 Pending CN117320759A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173849 2021-05-14
EP21173849.7 2021-05-14
PCT/EP2022/062985 WO2022238553A1 (en) 2021-05-14 2022-05-12 Radiopharmaceutical somatostatin receptor ligands and precursors thereof

Publications (1)

Publication Number Publication Date
CN117320759A true CN117320759A (zh) 2023-12-29

Family

ID=75936725

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280035052.5A Pending CN117320759A (zh) 2021-05-14 2022-05-12 放射性药物生长抑素受体配体及其前体

Country Status (11)

Country Link
US (1) US20240317780A1 (https=)
EP (1) EP4337270A1 (https=)
JP (1) JP2024517971A (https=)
KR (1) KR20240008341A (https=)
CN (1) CN117320759A (https=)
AU (1) AU2022273184A1 (https=)
BR (1) BR112023023890A2 (https=)
CA (1) CA3214915A1 (https=)
IL (1) IL308414A (https=)
MX (1) MX2023013485A (https=)
WO (1) WO2022238553A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117777296A (zh) * 2024-02-28 2024-03-29 北京肿瘤医院(北京大学肿瘤医院) B7h3亲和体及其诊疗核素标记物的制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE070098T2 (hu) * 2017-07-28 2025-05-28 Univ Muenchen Tech Kettõs módusú radioaktív jelzõ és terapeutikumok

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117777296A (zh) * 2024-02-28 2024-03-29 北京肿瘤医院(北京大学肿瘤医院) B7h3亲和体及其诊疗核素标记物的制备方法与应用
CN117777296B (zh) * 2024-02-28 2024-05-28 北京肿瘤医院(北京大学肿瘤医院) B7h3亲和体及其诊疗核素标记物的制备方法与应用

Also Published As

Publication number Publication date
BR112023023890A2 (pt) 2024-01-30
IL308414A (en) 2024-01-01
WO2022238553A1 (en) 2022-11-17
US20240317780A1 (en) 2024-09-26
KR20240008341A (ko) 2024-01-18
AU2022273184A1 (en) 2023-10-12
MX2023013485A (es) 2023-12-07
CA3214915A1 (en) 2022-11-17
EP4337270A1 (en) 2024-03-20
JP2024517971A (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
AU2018308699B2 (en) Dual mode radiotracer and -therapeutics
CN103533963B (zh) 用通过nota络合的[18]氟化铝标记的her2结合肽
US20210402016A1 (en) Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
CN116751259A (zh) 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法
CN103402550A (zh) 用含有18f的有机硅化合物标记的her2结合肽
EP4043041A1 (en) Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
CN117320759A (zh) 放射性药物生长抑素受体配体及其前体
JP6410339B2 (ja) 放射性核種標識オクトレオチド誘導体
US20250313579A1 (en) Ligand compounds comprising a chelating group as a bridging group
AU2020405585A1 (en) Modified GRPR antagonist peptides for imaging and therapy of cancer
EP4631959A2 (en) Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy
CN119630622A (zh) 用于放射性药物的硅系氟化物受体基团
WO2025162868A1 (en) Compounds comprising a silicon-based fluoride acceptor group useful as radiopharmceutical compounds
EA052681B1 (ru) Лигандные соединения, содержащие хелатирующую группу в качестве мостиковой группы
US20260077073A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof
HK40022705A (en) Dual mode radiotracer and -therapeutics
HK40022705B (en) Dual mode radiotracer and -therapeutics
HK1193987A (en) Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota
HK1191244A (en) Her2 binding peptides labelled with a 18f - containing organosilicon compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination